Arvinas’ Stock Skyrockets by 75% with Cancer Targeting Protein Degrader

Photo of author
Written By Elizabeth Monroe

Over the last five months or so, Arvinas’ stock trades at around $38, reflecting an increase of over 75%.

This surge is attributed to a successful bull run between November and February, where shares escalated from $15 to more than $50 before experiencing a slight decline.

The primary catalyst for this upswing was the progress of Arvinas’ lead asset, vepdegestrant, an estrogen receptor (ER) protein degrader targeting ER+/HER2- breast cancer, developed in partnership with Pfizer.

Vepdegestrant’s Development and Market Response

In 2021, Pfizer invested heavily in vepdegestrant, paying Arvinas $650 million upfront, making a $350 million equity investment, and committing up to $1.4 billion in milestone payments, plus profit and cost-sharing on global sales pending approval.

Credit: DepositPhotos

Initially, phase 1 data showed modest results with one confirmed partial response and a clinical benefit rate (CBR) of 42% among 12 patients.

However, phase 2 data presented in November 2022 was less promising, displaying only two partial responses out of 71 patients.

Comparative Analysis with Competitors

This lukewarm data set led to skepticism about the drug’s efficacy, especially in light of failures from other companies like Sanofi and Roche, who had similar projects targeting breast cancer.

Despite these challenges, Arvinas noted a CBR of 38% across all study participants, which improved to 51% among patients with ESR1 mutations.

Strategic Moves and Market Impact

The rebound in Arvinas’ share price came after revealing results from a combination study of vepdegestrant with Pfizer’s Ibrance, showing a 42% overall response rate and 11.1 months of median progression-free survival among heavily treated patients.

This led to the initiation of pivotal combination studies, VERITAC-2 and VERITAC-3, focusing on vepdegestrant as a monotherapy and in combination with Ibrance respectively, with results expected in the second half of 2024.

Expanding into Prostate Cancer

Arvinas recently announced a significant licensing agreement with Novartis for the development and commercialization of ARV-766, Arvinas’ second-generation androgen receptor degrader for prostate cancer. This deal includes an upfront payment of $150 million to Arvinas, with potential development, regulatory, and commercial milestones up to $1.01 billion, plus tiered royalties.

This strategic partnership highlights the continued interest in protein degradation technologies in targeting complex cancers.

Novartis’ Strategic Position in Oncology

Novartis, a pharmaceutical giant with $45.44 billion in 2023 revenues, places a strong emphasis on its oncology segment, which includes multiple blockbuster drugs.

The company’s newest prostate cancer therapy, Pluvicto, has shown promising results and significant revenue potential.

The partnership with Arvinas for ARV-766 could potentially enhance Novartis’ offerings in the prostate cancer market, aligning with its long-term strategy to dominate this therapeutic area.

Future Prospects and Market Dynamics

The collaboration between Arvinas and Novartis not only diversifies Arvinas’ risk but also enhances its credibility and financial stability in the competitive biotech landscape.

Credit: DepositPhotos

For Novartis, acquiring a promising asset like ARV-766 could safeguard its competitive edge in oncology, particularly if the drug’s clinical trials yield positive results.

Close Monitoring of Clinical Trial Results Recommended

The strategic maneuvers by Arvinas, coupled with the partnership with Novartis, highlight a proactive approach to navigating the complexities of drug development and commercialization.

Investors in both companies should monitor upcoming clinical trial results closely, as these will significantly influence the companies’ stock performances and strategic directions.

The biotech sector remains volatile, and while the potential for high returns exists, so does the risk of rapid declines based on clinical outcomes.


You should read and understand this disclaimer in its entirety before joining or viewing the website or email/blog list of (the “Publisher”). The information (collectively the “Advertisement”) disseminated by email, text or other method by the Publisher including this publication is a paid commercial advertisement and should not be relied upon for making an investment decision or any other purpose. The Publisher is engaged in the business of marketing and advertising the securities of publicly traded companies in exchange for compensation. The track record, gains, upside, and/or losses mentioned in the Advertisement, if any, should not be considered as true or accurate or be the basis for an investment. The Publisher does not verify the accuracy or completeness of any information included in the Advertisement. While the Publisher does not charge for the SMS service, standard carrier message and data rates may apply. To unsubscribe from receiving promotional text messages to your phone sent via an autodialer, using your phone reply to the sender’s phone number with the word STOP or HELP for help.

The Advertisement is not a solicitation or recommendation to buy securities of the advertised company. An offer to buy or sell securities can be made only by a disclosure document that complies with applicable securities laws and only in the states or other jurisdictions in which the security is eligible for sale. The Advertisement is not a disclosure document. The Advertisement is only a favorable snapshot of unverified information about the advertised company. An investor considering purchasing the securities, should always do so only with the assistance of his legal, tax and investment advisors. Investors should review with his or her investment advisor, tax advisor or attorney, if and to the extent available, any information concerning a potential investment at the web sites of the U.S. Securities and Exchange Commission (the "SEC") at; the Financial Industry Regulatory Authority (the "FINRA") at, and relevant State Securities Administrator website and the OTC Markets website at The Publisher cautions investors to read the SEC advisory to investors concerning Internet Stock Fraud at, as well as related information published by the FINRA on how to invest carefully. Investors are responsible for verifying all information in the Advertisement. As an advertiser, we do not verify any information we publish. The Advertisement should not be considered true or complete.

The Publisher does not offer investment advice or analysis, and the Publisher further urges you to consult your own independent tax, business, financial and investment advisors concerning any investment you make in securities particularly those quoted on the OTC Markets. Investing in securities is highly speculative and carries an extremely high degree of risk. You could lose your entire investment if you invest in any company mentioned in the Advertisement. You acknowledge that we are not an investment advisory service, a broker-dealer or an investment adviser and we are not qualified to act as such. You acknowledge that you will consult with your own independent, tax, financial and/or legal advisers regarding any decisions as to any company mentioned here. We have not determined if the Advertisement is accurate, correct or truthful. The Advertisement is compiled from publicly available information, which include, but are not limited to, no cost online research, magazines, newspapers, reports filed with the SEC or information furnished by way of press releases. Because all information relied upon by us in preparing an advertisement about an issuer comes from a public source, it is not reliable, and you should not assume it is accurate or complete.

By your subscription to our profiles, the viewing of this profile and/or use of our website, you have agreed and acknowledged the terms of our full disclaimer and privacy policy which can be viewed at the following link: and

By accepting the Advertisement, you agree and acknowledge that any hyperlinks to the website of (1) a client company, (2) the party issuing or preparing the information for the company, or (3) other information contained in the Advertisement is provided only for your reference and convenience. The advertiser is not responsible for the accuracy or reliability of these external sites, nor is it responsible for the content, opinions, products or other materials on external sites or information sources. If you use, act upon or make decisions in reliance on information contained in any disseminated report/release or any hyperlink, you do so at your own risk and agree to hold us, our officers, directors, shareholders, affiliates and agents harmless. You acknowledge that you are not relying on the Publisher, and we are not liable for, any actions taken by you based on any information contained in any disseminated email or hyperlink.